Skip to main content

Table 1 Serum concentration of osteopontin (OPN) and thrombospondin-1 (TSP-1) according to baseline patients characteristics

From: Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer

  No (%) OPN serum level TSP-1 serum level
   Median (range) p value Median (range) p value
Population
 Controls 20 8.8 (4–46)   31 (0–12060)  
 Patients 171 (100) 27.6 (7–191) <1.10e-5 14520 (2946–30940) <1.10e-5
Age, years (range)
 <65 138 (81) 26.3 (7–89)   15057 (3979–30938)  
 ≥65 33 (19) 32.1 (9–191) 0.07 13171 (2946–22011) 0.01
Sex
 Female 62 (36) 26.6 (7–89)   14910 (2946–30938)  
 Male 109 (64) 28.2 (8–191) 0.17 13980 (3381–26077) 0.31
Smoking history
 Current 87 (51) 27.9 (7–88)   15062 (2946–30938)  
 Former 56 (33) 27.9 (7–191)   13171 (3381–26077)  
 Never 27 (16) 25.0 (9–89) 0.85 14762 (5564–20468) 0.17
p TNM
 IA 40 (23) 23.3 (11–89)   15270 (3381–25112)  
 IB 41 (24) 24.5 (7–87)   13120 (4899–26906)  
 IIA 21 (12) 26.7 (8–88)   12928 (7047–24731)  
 IIB 16 (9) 30.1 (9–78)   14440 (9043–23813)  
 IIIA 40 (24) 33.4 (8–148)   13639 (5450–30938)  
 IIIB 5 (3) 37.5 (17–191)   14816 (12862–20606)  
 IV 8 (5) 26.4 (9–64) 0.17 16332 (2946–22299) 0.75
Stage
 I-II-IIIA 158 (92) 27.4 (7–148)   14423 (3381–30938)  
 IIIB 13 (8) 29.6 (9–191) 0.75 16324 (2946–22299) 0.23
Tumor size
 <5 cm 125 (74) 23.3 (7–89)   14107 (2946–30938)  
 ≥5cm 43 (26) 34.6 (9–191) <1.10e-5 15057 (5450.5-23813) 0.53
Type of resection
 Wedge 22 (14) 26.11 (8–89)   13403 (2946–22299)  
 Lobectomy 123 (77) 26.8 (7–148)   15062.(3381–26906)  
 Bi-lobectomy 6 (4) 31.2 (12–191)   15804(11052–21302)  
 Pneumonectomy 9 (6) 38.3 (9–85) 0.17 10526 (5929–30938) 0.07
Resection margins
 Clear 165 (98) 27.2 (7–191)   14519 (2946–30938)  
 Involved 4 (2) 54.5 (9–75) 0.26 15410 (12605–22011) 0.43
Histologic subtype
 Adenocarcinoma 108 (63) 25.3 (7–148)   14799 (2946–26906)  
 Squamous cell carcinoma 40 (23) 32.8 (8–88)   13032 (5327–30938)  
 Large cell carcinoma 8 (5) 36.3 (21–72)   15720 (12480–22299)  
 Other 15 (9) 29.6 (9–191) 0.06 12605 (5564–24731) 0.29
Lympho-vasc. invasion
 Yes 42 (26) 28.4 (9–191)   14202 (2946–24731)  
 No 123 (75) 27.6 (7–148) 0.47 14567 (3979–30938) 0.75
Pleural invasion      
 Yes 74 (46) 28.3 (7–191)   13811 (2946–26077)  
 No 86 (54) 26.9 (8–89) 0.36 15247 (3381–30938) 0.27
Adjuvant treatment
 Yes 48 (29) 28.1 (7–191)   14608 (5327–24731)  
 No 120 (71) 26.9 (8–148) 0.69 14543 (2946–30938] 0.66
EGFR status
 Wild-type 112 (90) 26.8 (7–191)   13752 (2946–26906)  
 Mutation 12 (10) 24.6 (10–38) 0.37 15984 (10111–22165) 0.23
KRAS status
 Wild-type 78 (62) 27.4 (7–188)   13171 (2946–26906)  
 Mutation 48 (38) 24.7 (7–191) 0.37 15323 (5327–25112) 0.08
ALK rearrangement
 Yes 3 (2) 29.6 (22–64)   19801 (14519–22299)  
 No 164 (98) 27.2 (7–191) 0.50 14440 (2946–30938) 0.13